Join
Live feed
·
PRReleasevia Quantisnow
Olema Pharmaceuticals Inc. logo

Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
OLMA· Olema Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track OLMA (Olema Pharmaceuticals Inc.) and more on Quantisnow.